1. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes 
Solomon L. Woldu, Joseph A. Moore, Bo Ci, Yuval Freifeld, Timothy N. Clinton, Ahmet M. Aydin, Nirmish Singla, Laura-Maria Krabbe, Ryan C. Hutchinson, James F. Amatruda, Arthur Sagalowsky, Yair Lotan, Yull Arriaga, Vitaly Margulis, Yang Xie, Aditya Bagrodia 
European Urology Oncology 
Volume 1, Issue 3, Pages (August 2018)
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Patient selection flow chart. NSGCT=nonseminomatous germ cell tumor; NOS=not otherwise specified; AJCC=American Joint Committee on Cancer; PC-RPLND=postchemotherapy retroperitoneal lymph node dissection.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Overall survival (OS) stratified by receipt of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for (A) the unmatched cohort; (B) the propensity score–matched cohort; and (C) the propensity score–matched cohort with 6-mo landmark analysis.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

4. Fig. 3
Overall survival (OS) stratified by pathologic nodal status. PC-RPLND=postchemotherapy retroperitoneal lymph node dissection.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions